UK Markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.02-0.18 (-0.56%)
At close: 04:00PM EST
32.41 +0.39 (+1.22%)
After hours: 04:23PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.46
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 374.77
52-week low 326.81
50-day moving average 332.48
200-day moving average 338.55

Share statistics

Avg vol (3-month) 3868.72k
Avg vol (10-day) 3933.94k
Shares outstanding 5104.53M
Implied shares outstanding 6N/A
Float 8103.17M
% held by insiders 12.56%
% held by institutions 169.59%
Shares short (13 Oct 2022) 43.94M
Short ratio (13 Oct 2022) 44.72
Short % of float (13 Oct 2022) 44.34%
Short % of shares outstanding (13 Oct 2022) 43.72%
Shares short (prior month 14 Sept 2022) 44.26M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -61.58%
Operating margin (ttm)-63.84%

Management effectiveness

Return on assets (ttm)-13.41%
Return on equity (ttm)-33.79%

Income statement

Revenue (ttm)249.94M
Revenue per share (ttm)2.38
Quarterly revenue growth (yoy)-29.40%
Gross profit (ttm)138.29M
EBITDA -149.3M
Net income avi to common (ttm)-153.93M
Diluted EPS (ttm)-1.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)416.5M
Total cash per share (mrq)3.93
Total debt (mrq)81.11M
Total debt/equity (mrq)17.11
Current ratio (mrq)3.37
Book value per share (mrq)4.40

Cash flow statement

Operating cash flow (ttm)-91.58M
Levered free cash flow (ttm)-66.47M